This research paper, published in Research Square, investigates the long-term cardiovascular impact of COVID-19 on patients with pre-existing coronary artery disease (CAD). By tracking patients over a two-year period, the authors reveal that COVID-19 survivors with CAD experience a persistent, "hypercoagulable" state—meaning their blood clots more easily and more strongly—long after the initial viral infection has cleared.
TL;DR
COVID-19 survivors with coronary artery disease (CAD) remain in a high-risk "hypercoagulable" state for at least two years after recovery. This persistent clotting risk is closely linked to elevated neutrophil levels, suggesting that the immune system continues to drive cardiovascular risk long after the respiratory symptoms of COVID-19 have vanished.
What Problem Does This Paper Address?
Both CAD and COVID-19 are known to put the body into a pro-thrombotic (clot-promoting) state. When a patient has both, they face a "double-hit" scenario: the underlying vessel damage of CAD combined with the systemic inflammation of COVID-19.
While the acute clotting risks of COVID-19 (like strokes and pulmonary embolisms) are well-documented, we know much less about the long-term "tail" of this risk. Does the blood return to a normal state after recovery, or does the "double-hit" create a lasting vulnerability? This paper seeks to map the two-year trajectory of coagulation function in these high-risk survivors to determine if standard recovery protocols are sufficient.
Methods
The researchers conducted a retrospective, single-center study at Shanghai Pudong Hospital, following 117 CAD patients admitted between March and June 2021. They split the cohort into two groups: 60 who had COVID-19 and 57 who did not (the control group).
The study’s technical edge lies in its use of Thromboelastography (TEG) alongside standard coagulation tests.
- Standard Tests: Measure isolated factors in plasma (like Prothrombin Time or Fibrinogen).
- TEG: A dynamic test that looks at the physical properties of a clot as it forms in whole blood. It measures how long it takes to start a clot (R-time), how fast it reaches a certain thickness (K-time and α-angle), and the ultimate strength of the clot (Maximum Amplitude, or MA).
Data was collected at admission and at one- and two-year follow-up intervals.
Datasets
The study utilized a proprietary clinical dataset from Shanghai Pudong Hospital. It included:
- Patient Demographics: Age, gender, and comorbidities (Diabetes, Hypertension, COPD).
- Biomarkers: NT-proBNP (cardiac stress), D-dimer (clot breakdown), and full blood counts.
- Coagulation Profiles: Comprehensive TEG and conventional lab results.
No external or public benchmarks were used, as this was a longitudinal clinical observation.
Key Insights and Ideas
- The "Invisible" Risk: Perhaps the most striking finding was that standard coagulation tests (PT, INR, APTT) often appeared normal in COVID-19 survivors. However, the TEG results told a different story, showing significantly faster and stronger clot formation. This suggests that standard labs may provide a false sense of security for recovering patients.
- Immunothrombosis in the Long-Tail: The study found a persistent elevation of neutrophils (white blood cells) in the COVID-19 group. Crucially, these neutrophil levels correlated positively with clot strength (MA). This points toward "immunothrombosis"—a process where the immune system’s inflammatory response directly triggers the clotting cascade.
- Two-Year Persistence: The hypercoagulable state didn't resolve after the first year; it was still clearly present at the two-year mark. This suggests that COVID-19 may "reprogram" the inflammatory-coagulation axis in CAD patients for a much longer duration than previously thought.
Key Results
- TEG Parameters: At both one and two years post-discharge, the COVID-19 group showed significantly shorter R and K times (faster clotting) and higher MA and α-angles (stronger, faster-growing clots) compared to the control group ($P < 0.05$).
- Neutrophil Levels: Neutrophil counts in the COVID-19 group were significantly higher at one year ($5.597 \times 10^9/L$) and two years ($5.763 \times 10^9/L$) compared to their baseline ($4.101 \times 10^9/L$).
- Correlation: There was a statistically significant positive correlation between neutrophil levels and clot strength (MA) at both the one-year ($r = 0.2929, P = 0.0231$) and two-year marks ($r = 0.2976, P = 0.0209$).
- D-dimer: While it eventually stabilized, D-dimer levels were significantly higher in the COVID-19 group one year after discharge ($P = 0.0162$).
Limitations and Future Work
The authors acknowledge several limitations:
- Single-Center Scope: The findings are based on a specific population in Shanghai, which may limit generalizability.
- Sampling Frequency: Data was only taken at yearly intervals. More frequent "snapshots" (e.g., every 3 months) would provide a clearer picture of the recovery curve.
- Mechanistic Proof: While the correlation between neutrophils and clotting is strong, the study did not directly measure Neutrophil Extracellular Traps (NETs)—the physical "webs" neutrophils cast to catch pathogens that also trap platelets—to definitively prove the causal pathway.
Future Directions: The authors call for multicenter trials and research into whether targeted anti-inflammatory therapies or personalized anticoagulation strategies (guided by TEG) could reduce the long-term thrombotic burden in these survivors.
Summary updated